- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01332032
Promoting Breast Cancer Screening in Non-adherent Women
This randomized study compares the effectiveness and cost-effectiveness of 3 proven methods of reaching out to women who are coming due for or who are overdue for a mammogram. The study originally embedded in a community healthcare plan and an associated community clinic, now accepts patients using the community clinic and 3 other health care plans. The study makes use of a complex computer driven reminder system.
The study also will examine ways to improve the efficiency and sequencing of the interventions by identifying patient factors associated with intervention effectiveness.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The randomized study compares three interventions. All eligible women are randomly assigned to 1 of 3 interventions. If they become 18 or more months from a prior mammogram, they will receive the intervention to which they were assigned.
The 3 arms are
- RL ARM: (reminder letter) a control arm which consists of a reminder letter only that states when the last mammogram was, contains a standard recommendation from her primary care provider (PCP), and requests that the woman call a special number for help scheduling a mammogram.
- RC ARM: (reminder call) a reminder letter as above, followed, if no response, by a reminder call from a study scheduler who offers to help schedule a mammogram.
- ETTC ARM: (enhanced tailored telephone counseling call) a reminder letter as above, followed, if no response by a second letter, a mammography educational booklet and a second request to call a special number to schedule a mammogram. If no response, a study counselor/educator will call.
A complex computer-based tracking system identifies women coming due for a mammogram or those overdue for a mammogram. The system interfaces with the clinic database systems and stores information re age, telephone number, address, prior screening dates, primary care provider name, scheduling dates, etc. The system can generate reminder letters as appropriate.
The tracking system also interfaces with computer-assisted telephone script systems(CATI) which prompt the study scheduler or the study counselor to follow the protocol that is tailored to the individual patient.
The CATI system captures data from all calls, including how ready a woman is to schedule, the answers to a brief socio-demographic survey and in the counselor call script barriers and misinformation about mammography.
The computer system also interfaces with the radiology scheduling system so that study personnel can assist women in scheduling a mammogram during the phone call.
The primary outcome is the number of women in each arm getting a mammogram. This data will come from the clinic data base and the healthcare plan billing system.
Secondary outcomes include evaluation of the effect of booster or repeat interventions in women failing to respond to prior request for mammogram.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Reliant Medical Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women aged 40 through 84 years old
- in the Fallon Community Health Plan, Blue Cross, Tufts or Harvard Pilgrim health plans for 18 or more months
- has a current Reliant Medical Group (formerly called Fallon Clinic) primary care provider
- has working telephone
Exclusion Criteria:
- significant cognitive impairment
- serious illness, precluding screening
- bilateral mastectomy
- life expectancy less than 5 years
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Reminder Letter
A letter sent to women reminding them that are coming due or overdue for a mammogram.
It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years.
It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider.
Repeat "Booster" letters will be sent in subsequent years to those failing to get a mammogram.
|
A letter sent to women reminding them that they are coming due or overdue for a mammogram.
It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider.
For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E.
reminder letter) will be sent.
The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one.
Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
Other Names:
|
|
Reminder Call
A reminder letter (as in the 1st group) is sent.
If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her.
Repeat "Booster" letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram.
|
A reminder letter (as in the 1st group) is sent.
If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her.
For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram.
The letter reminds her that her PCP recommends she get a mammogram.
Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
Other Names:
|
|
Counselor Call
A reminder letter as above is sent first.
If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet.
The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule.
If a woman does not schedule within 8-10 days, a counselor will call.
The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing.
Repeat "booster" letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram.
techniques.
Average calls last 20-30 minutes.
|
Reminder letter s as above is sent.
If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet.
Second letter reiterates reminder that PCP recommends screening.
Has number to call to schedule.
If subject does not schedule within 2 weeks, counselor will call.
Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques.
For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of women in each arm who complete a mammogram in the prior 24 months
Time Frame: 4 years
|
The outcome will be determined for each of the 4 years of intervention.
But the main interest will be the outcome measured in the final intervention year because we believe this best illustrates the magnitude of intervention effect that could be achieved in future years.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A comparison of the number of interventions required per arm
Time Frame: 4 years
|
We anticipate that fewer women who receive the ETTC call (Counselor call) will need repeat interventions compared with the women in the reminder call arm or the women in the reminder letter arm.
|
4 years
|
|
The percent of women in each arm receiving an intervention who will complete a scheduled mammogram
Time Frame: 4 years
|
We anticipate that women who received a counselor (ETTC) call and who scheduled a mammogram on the call will have the highest completion rate compared to women who received a reminder call or a reminder letter.
|
4 years
|
|
Evaluation of the effectiveness of booster or repeat interventions in women failing to respond to request for getting a mammogram
Time Frame: 4 years
|
The relative effectiveness and cost effectiveness of repeating reminders (letters, calls vs. counseling calls) in women who have not responded to a prior request(s) for completing a mammogram will be studied.
|
4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mary E Costanza, MD, UMass Medical School and Reliant Medical Group (formerly called Fallon Clinic)
- Principal Investigator: Roger Luckmann, MD, MPH, UMass Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FCM001
- R01CA132935 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Reminder Letter
-
Public Health EnglandWithdrawnInfluenza, Human
-
University Hospital, ToursCompleted
-
Nantes University HospitalActive, not recruiting
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR)CompletedGestational DiabetesCanada
-
Universiteit AntwerpenThomas More University of Applied Sciences; Stichting tegen Kanker; Intermutualistic... and other collaboratorsCompletedHealth Behavior | Breast Cancer Screening | MammographyBelgium
-
Wills EyeThomas Jefferson UniversityCompleted
-
Finnish Institute for Health and WelfareCompletedHealth Behavior | Health Care Utilization | Health Care Seeking BehaviorFinland
-
British Columbia Cancer AgencyCanadian Breast Cancer FoundationCompleted
-
The Cleveland ClinicCompletedConflicts of Interest
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed